Low-dose interleukin-2 promotes immune regulation in face transplantation: A pilot study
Murakami N, Borges T, Win T, Abarzua P, Tasigiorgos S, Kollar B, Barrera V, Ho Sui S, Teague J, Bueno E, Clark R, Lian C, Murphy G, Pomahac B, Riella L. Low-dose interleukin-2 promotes immune regulation in face transplantation: A pilot study. American Journal Of Transplantation 2023, 23: 549-558. PMID: 36740193, PMCID: PMC10318113, DOI: 10.1016/j.ajt.2023.01.016.Peer-Reviewed Original ResearchConceptsLow-dose IL-2 therapyIL-2 therapySkin allograftsFace transplant recipientsTransplant recipientsIL-2Immune regulationLow-dose interleukin-2 (IL-2) therapyHigher acute rejection ratesLow-dose IL-2Face transplantationAcute rejection ratesCytotoxicity-associated genesDose interleukin-2Greater suppressive functionInterleukin-2 therapyAutoimmune hemolytic anemiaRegulatory T cellsNarrow therapeutic windowLife-changing procedureImmunological monitoringTim-3Peripheral bloodImmune modulationHemolytic anemia